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Introduction
Survival rates after childhood cancer now approach 80% in developed countries as a result of enhanced stratification, more effective treatment and optimized supportive care (Gatta et al., 2014) . The increasing number of childhood cancer survivors (CCS) has led to the growing awareness of chronic health effects resulting from treatment for childhood cancer (Geenen et al., 2007; Oeffinger et al., 2006) . Examples of long-term consequences include hearing impairment, gonadal impairment and cardiotoxicity. The inter-individual variability in the number and magnitude of health problems in similarly treated CCS suggests that genetic variation modifies the association between treatment and risk of late toxicity.
To identify such genetic variants two common approaches have been applied: a candidate gene approach, and more recently, the genome wide association study (GWAS) approach. Candidate gene studies focus on associations between genetic variation within prespecified genes of interest and specific outcomes, while GWASs are hypothesis-free searches that can identify novel single-nucleotide polymorphisms (SNPs) that potentially modify the risk of a late toxicity.
After completion of the Human Genome Project (HGP) (HumanGenomeProject, 2015) in 2003 and the International HapMap project, GWASs have discovered many thousands of genetic variants associated with a variety of diseases (EMBL-EBI, 2017) , which catalyzed research on genetic variation underlying late toxicity among cancer survivors (MacArthur et al., 2017) . Except for cardiotoxicity (Aminkeng et al., 2016a) , the resulting number of genetic variation studies in CCS have not produced unambiguous evidence in this field. The lack of strong evidence has impeded translation into clinical practice, such as patient counseling or dose-reduction trials. In contrast, genotyping of childhood cancer patients in order to risk-adapt treatment based on risk models predicting susceptibility to specific toxicities is expected to become standard of care. A comprehensive review of genetic aspects of acute toxicity was recently published (Mapes et al., 2017) . However, a recent overview of genetic susceptibility studies concerning late toxicities in CCS is not yet available.
An international collaboration is currently working on the identification of genetic determinants associated with hearing impairment and female gonadal impairment, in a large cohort of CCS (European Union's Seventh Framework programme project PanCareLIFE). In the current study, we summarize the results of a systematic literature search and evaluate the results and quality of available literature on genetic susceptibility of these two late toxicities (hearing impairment and female gonadal impairment) and three hormone-related late toxicities (male Fig. 1 . Flowchart study selection process Review Genetics of Late Effects. E. Clemens et al. Critical Reviews in Oncology / Hematology 126 (2018) [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] Table 1 Overview of studies on the influence of genetic variation on components of metabolic syndrome in CCS. Where applicable, the multivariable analysis of the combined results of the discovery and replication cohort are reported. If no replication cohort was included, multivariable analysis of the discovery cohort is reported, or univariate analysis of the discovery if multivariable analysis was missing.
Where applicable, the adjusted p-value corrected for multiple testing was reported.
Table 2
Overview of studies on the influence of genetic variation on gonadal impairment in CCS. Where applicable, the multivariable analysis of the combined results of the discovery and replication cohort are reported. If no replication cohort was included, multivariable analysis of the discovery cohort is reported, or univariate analysis of the discovery if multivariable analysis was missing. Where applicable, the adjusted p-value corrected for multiple testing was reported. Table 3 Overview of studies on the influence of genetic variation on bone mineral density in CCS. Abbreviations: CRT = cranial radiotherapy, N/A = not applicable, NA = not available.
P-values in bold are considered statistically significant by the authors of the original article. Ethnic race is stated if reported in original article. Where applicable, the multivariable analysis of the combined results of the discovery and replication cohort are reported. If no replication cohort was included, multivariable analysis of the discovery cohort is reported, or univariate analysis of the discovery if multivariable analysis was missing.
Table 4
Overview of studies on the influence of genetic variation on hearing impairment in CCS. Where applicable, the multivariable analysis of the combined results of the discovery and replication cohort are reported. If no replication cohort was included, multivariable analysis of the discovery cohort is reported, or univariate analysis of the discovery if multivariable analysis was missing.
gonadal impairment, metabolic risk factors and bone mineral density impairment).
Methods

Search strategy
To provide an overview of the established genetic susceptibility factors associated with late toxicities in childhood cancer survivors, we identified relevant articles, published up until September 2017, by systematically searching Embase, Cochrane, Google Scholar, MEDLINE and Web of science. Details of the full search strategy for each database are included in Appendix I. The computer-based searches were conducted by a medical information specialist at the university medical library in the Erasmus Medical Center.
Definitions
The majority (> 80%) of the cohort in every article had to be diagnosed with cancer ≤21 years of age. As we were specifically interested in 'late' toxicity, defined as toxicity still apparent at follow-up after end of treatment, we only included studies that evaluated metabolic risk factors, bone mineral density, gonadal impairment or hearing impairment in CCS present after end of treatment regardless of followup time. Definition of endpoints used by the authors were extracted from the corresponding papers and assembled in tables.
Study selection
Two independent investigators (EC and ALFvdK) reviewed all titles and abstracts, and independently selected potentially eligible studies. Case series, case reports, abstracts or reviews were excluded. Only studies published in English were selected for the analysis. Disagreements were resolved through consensus. Full text papers were retrieved to assess fulfillment of the selection criteria (Fig. 1) . Cross reference check was performed to identify additional studies that were potentially overlooked during the initial search. Authors were contacted to clarify or supplement their results where necessary.
Results & discussion
The search strategy yielded 2762 unique records (Fig. 1) . After screening titles and abstracts 148 articles were selected for detailed evaluation of full texts. For the purpose of the current review we focused on gene-association studies of metabolic syndrome, low bone mineral density, and gonadal impairment and hearing impairment. As a result, 27 articles were considered in this review, including seven studies on metabolic syndrome (six candidate gene studies and one GWAS), six candidate gene studies of low bone mineral density, two candidate gene studies of gonadal impairment, and 12 candidate gene studies of hearing impairment (Tables 1-4).
Of the candidate gene studies, 50% (13/26) had less than 100 participants while 80% (21/26) had less than 200 participants. Only two included a cohort of more than 500 CCS (n = 532 and n = 600) (Van Waas et al., 2013; Ross et al., 2004) . Only six of the candidate studies (23%) adjusted for multiple testing to reduce the chance of type I error (false positive results), which would take into account the multiple models tested (Van Dorp et al., 2013; Park et al., 2016; Thiesen et al., 2017; Brown et al., 2015; Choeyprasert et al., 2013; Ross et al., 2009) . One candidate study investigated both metabolic syndrome and bone mineral density (Van Waas et al., 2013) . Where possible, the multivariable analysis of the combined results of the discovery and replication cohort are reported (Tables 1-4) . Where applicable, the adjusted p-value corrected for multiple testing was reported.
Metabolic syndrome components
The prevalence of components of the metabolic syndrome, including obesity, hypertension, dyslipidemia and type 2 diabetes (or specifically hyperglycemia or hyperinsulinemia), has been reported to be higher in CCS compared to the general population (Dalton et al., 2003; Rogers et al., 2005; van Waas et al., 2010; Taskinen et al., 2000) . Six candidate gene studies and one GWAS investigated polymorphisms associated with different aspects of metabolic syndrome. The polymorphisms in the candidate gene studies had been identified previously in GWASs performed in the general population or were based on the genes coding for hormones (or its receptor) associated with obesity. No studies addressed the genetic susceptibility of dyslipidemia. The only variants that had been investigated in multiple independent cohorts (Table 1) were variants within the gene coding for the leptin receptor (LEPR) which were evaluated because of their hypothesized functional contribution to obesity.
Leptin, a hormone secreted in adipocytes, has a key role in increasing satiety and energy homeostasis (Allison and Myers, 2014) . Leptin insensitivity has been reported to be associated with obesity, leading to the hypothesis that obesity in CCS may be influenced by a carrier status of polymorphisms in the leptin receptor (LEPR) (Ross et al., 2004) . Only one (Ross et al., 2004) of the three independent candidate gene studies in CCS that investigated the leptin pathway found a statistically significant correlation between a polymorphism in LEPR (GlnQ223Arg) and higher odds of being obese (Ross et al., 2004; Sawicka-Zkowska et al., 2013; Skoczen et al., 2011) . The effect was sexdependent and after stratification on sex, it was only significant in females (n = 294, OR 2.5 95% CI 1.3-4.8) and not in males (n = 306). In addition, in the female subgroup, a significant interaction with cranial radiation (> 20 Gy) (Ross et al., 2004) was observed, suggesting that the impact of the polymorphism is especially prominent in female survivors who were treated with cranial irradiation. The impact of cranial irradiation can for a large part be attributed to the subsequent increased risk for growth hormone deficiency. The association between the GlnQ223Arg LEPR polymorphism and obesity has not been validated in the other two candidate gene studies (Sawicka-Zkowska et al., 2013; Skoczen et al., 2011) , although cranial radiotherapy did amplify the association with leptin levels (Sawicka-Zkowska et al., 2013; Skoczen et al., 2011) . These two studies were small (77 and 74 survivors, respectively) as compared to the study by Ross (600 survivors) (Ross et al., 2004) , which suggests that this inconsistency may be due to lack of power, especially considering the possible need for stratification for sex, which both studies did not carry out (Sawicka-Zkowska et al., 2013; Skoczen et al., 2011) . Alternatively, this discrepancy in results could be due to a false positive result in the initial study by Ross et al, which did not include an independent replication cohort.
Using a candidate gene approach based on polymorphisms identified in GWASs in the general population, the association of seven polymorphisms (rs2681472, rs2681492, rs987237, rs7826222, rs864745, rs758597, and rs2943641) with respect to hypertension, waist circumference, diabetes and metabolic syndrome (defined as blood pressure ≥ 140/90 mmHg; BMI ≥30 kg/m 2 ; self-reported prevalence of diabetes, or serum total cholesterol ≥5.2 mmol/l) was investigated (Van Waas et al., 2013) . None of these SNPs were associated with the development of any single parameter of metabolic syndrome among CCS (Van Waas et al., 2013) , including the presence of diabetes, and adjustment for cranial and abdominal radiotherapy did not change these results. In contrast, cranial and abdominal radiotherapy were strongly associated with the presence of, or components of, metabolic syndrome. This may suggest that the impact of treatment, mainly radiotherapy, is more dominant than the influence of the tested variants on the components of metabolic syndrome (Van Waas et al., 2013) .
The most recent genetic study was a GWAS in CCS of the St. Jude Lifetime Cohort, performed to identify genetic variants associated with obesity (Wilson et al., 2015) . In this GWAS, the cohort was stratified on cranial radiation exposure. Next, 70% of the strata was used as discovery cohort and 30% as replication cohort. Neither strata showed polymorphisms in the LEPR gene to be associated with obesity (Wilson et al., 2015) . Polymorphisms in regions near or within the SOX11 and CDH18 genes, regulators of neuronal growth, repair, and connectivity (Haslinger et al., 2009; Hirano and Takeichi, 2012) increased the risk of obesity among cranial radiated CCS (Wilson et al., 2015) . On the other hand, a polymorphism in FAM155A, thought to disrupt the hypothalamic-pituitary axis (Wilson et al., 2015; Ge et al., 2005) , decreased the likelihood of obesity in cranial radiated CCS. These findings have not yet been investigated in independent cohorts. Nevertheless, it is important to stress that the observed genetic variation will only partly explain the total variation in obesity, as other environmental factors such as cancer treatment and lifestyle are of major importance. In this GWAS, the pseudo R 2 (a measure for the amount of variability explained) in the cranial radiated strata was 0.174 for the clinical risk factors model, and 0.303 for the clinical risk factors combined with the SNPs model (Wilson et al., 2015) . Despite a significant increase, it also shows that this complex human trait deserves further research to understand its pathophysiological mechanism and its genetic components. Although a polymorphism in the LEPR gene would be a logical genetic determinant of metabolic risk factors, the evidence to date for the association is limited.
Gonadal impairment
Two candidate gene approach studies examined gonadal impairment; one in female and one in male CCS, and neither included a replication cohort.
The candidate gene study in female CCS explored the association between genetic variation and gonadal impairment based on high or low AMH levels (Van Dorp et al., 2013) (Table 2) . Seven polymorphisms, each in a different gene, were evaluated. The polymorphisms had previously been identified in GWASs as associated with age at natural menopause in the general population (Stolk et al., 2009; He et al., 2010) . In this study in CCS, females with a heterozygous genotype for rs1172822 in the BRSK1 gene had higher odds of having a low AMH value (OR = 3.15, 95% CI 1.35-7.32, p = 0.008). A modifying effect of the SNPs on the impact of treatment was not specifically evaluated, but the OR was adjusted for alkylating agents score and abdominal radiotherapy. BRSK1 is expressed in the human forebrain and to a lesser extent in mammalian ovaries. Overexpression of the BRSK1 gene has been hypothesized to disturb hypothalamic-pituitary-ovary axis regulation by affecting the secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus (He et al., 2009) or to influence cellcycle progression since it is essential for centriole duplication.
In male non-CCS, estrogen receptor deficiencies and polymorphisms are associated with infertility, although the exact mechanism remains to be elucidated (Galan et al., 2005; Ferlin et al., 2007; Guarducci et al., 2006) . The only genetic study addressing estrogen receptor polymorphisms in 127 CCS examined 51 SNPs. This study did not adjust for multiple comparison and had no replication cohort, increasing the risk of type 1 errors. Only SNPs in the estrogen receptor α gene were associated with increased risk of developing azoospermia, and this effect was stronger in the subgroup treated with high cumulative doses of alkylating agents/cisplatin or lower doses with additional radiotherapy (Romerius et al., 2011) . Other polymorphisms, coding for androgen receptors and estrogen receptor β, were not found to be associated with infertility in these CCS.
In both male and female CCS only one candidate gene study has been performed to evaluate the genetic component of variation in longterm gonadal impairment. This variation needs further investigation, preferably in large GWASs with a replication cohort.
Bone mineral density impairment
Genetic variation in low bone mineral density (BMD) in CCS has been studied in six candidate gene studies (Table 3) , of which one candidate gene study included up to 100 SNPs and adjusted for multiple comparisons (Park et al., 2016) . The most recently published study (den Hoed et al., 2016) included a replication cohort, which failed to corroborate any of the earlier associations from the discovery cohort.
The CRHR1 gene has previously been found to be associated with impaired lung function in asthma patients (Tantisira et al., 2004) and it has been suggested that CRHR1 gene variants may also explain differences in susceptibility to exogenous corticosteroid therapy, thereby influencing lung function, but also BMD. The G allele of a polymorphism (rs1876828) in the CRHR1 gene was associated with lower BMD in male survivors of acute lymphoblastic leukemia (ALL) (p = 0.02), while, in contrast, a non-significant higher BMD was observed in female ALL survivors (p = 0.09) (Jones et al., 2008) . As previously indicated for obesity, stratification by gender can be valuable, which again stresses the need for adequately sized cohorts.
Te Winkel and colleagues investigated 69 and 83 ALL survivors for respectively two and seven polymorphisms of six candidate genes and published this in two articles that in previous studies had shown an association between BMD impairment in the general population (Alvarez-Hernandez et al., 2003; Fang et al., 2003; van Rossum et al., 2003; Lorentzon et al., 2001) . ALL survivors who were carriers of the vitamin D receptor (VDR) 5′-end haplotype 3 ha d an increased risk for lower lumbar spine BMD (te Winkel et al., 2010) . Similarly, the MTHFR gene T-allele (rs1801133) was also identified as a risk factor for lower total body BMD (te Winkel et al., 2011) . These studies also showed that carrier status of both VDR and MRHFR polymorphisms were associated with low BMD at diagnosis, before any treatment had been administered. However, the subsequent rate of BMD decline during treatment did not differ between carriers and non-carriers. Also, parameters of body composition were not different between carriers and non-carriers of the MTHFR and MTRR polymorphisms at diagnosis, nor during treatment or after treatment. This suggests that while genetic variation may play a role in BMD variation, it does not modify the effect of treatment on BMD in ALL patients (Gjesdal et al., 2006; van Meurs et al., 2004; Steer et al., 2009 ).
Hearing impairment
Hearing impairment is commonly observed after treatment of CCS with the platinum agents cisplatin and carboplatin, or after cranial radiation (Langer et al., 2013) . The effect of these treatments could be modified by genetic polymorphisms.
Twelve candidate gene studies have been performed, none of which included a discovery cohort larger than 250 subjects (Table 4 ). Only three of the studies included an independent replication cohort and to date, no GWAS has been published on CCS after completion of treatment.
In a study by Ross et al, in 53 CCS subjects almost 2000 SNPs in 220 key pharmacogenetic genes involved in the absorption, distribution, metabolism and elimination of drugs were genotyped. This study included an independent replication cohort of 109 CCS. They identified COMT and TPMT as genetic determinants of variation in hearing impairment between CCS (Ross et al., 2009) . Catechol O-methyltransferase (COMT) is involved in the metabolism of catechol drugs and is highly expressed on hair cells of the mouse (Du et al., 2008) . However, its role in auditory function remains unclear. Thiopurine S-methyltransferase (TPMT), involved in the metabolism of thiopurine drugs, has not yet been linked to cisplatin metabolism in the general population, although it has been demonstrated in murine inner ear cells to play a role in cisplatin metabolism and detoxification (Bhavsar et al., 2017; Lee et al., 2016) . Four additional studies aimed to replicate the previously identified associations of hearing impairment with COMT and TPMT. While one study confirmed these associations (Pussegoda et al., 2013) , albeit with smaller effect sizes, the other three did not (Thiesen et al., 2017; Hagleitner et al., 2014; Yang et al., 2013) . One small study in a population of 63 children with hearing function measured during cisplatin treatment, did not detect a significant association of TMPT and COMT polymorphisms in children with hearing impairment (Lanvers-Kaminsky et al., 2014) . Despite the functional validation of the TMPT marker in murine inner ear cells (Bhavsar et al., 2017) , uncertainty remains regarding whether COMT or TPMT polymorphisms are genetic risk factors for hearing impairment (Lanvers-Kaminsky et al., 2014) . Lack of replication may be due to different methods for defining hearing impairment (e.g., Brock classification, Münster grading system, SIOP Boston criteria, CTCAE classification, Chang grading), heterogeneity of the study cohorts in regards to treatment exposure and age at diagnosis, or small sample sizes. In the study by Yang et al, nearly all patients (91%) received the otoprotectant amifostine and all had cranial radiotherapy, both of which might mask genetic susceptibility (Yang et al., 2013) . However, in their small underpowered cohort of 41 survivors who did not receive amifostine or cranial radiation, the association between TMPT and hearing impairment are in line with the other studies (Ross et al., 2009; Pussegoda et al., 2013) . This highlights the importance of a homogenous population with a large sample size, in order to avoid type 2 errors. Polymorphisms in the low density lipoprotein-related protein 2, or megalin (LRP2) gene, which is expressed in the marginal cells of the stria vascularis in the inner ear, have been postulated to predispose to cisplatin-induced hearing impairment. Three studies investigated the association between the LRP2 gene polymorphism (rs2075252) and hearing impairment, of which one study showed that the prevalence of hearing impairment was higher in CCS who carried the A allele of this polymorphism (Choeyprasert et al., 2013; Ross et al., 2009; Riedemann et al., 2008) . However, this study did not include a replication cohort.
Another variant in this gene (rs2228171) was investigated in 68 CCS and was found to be significant, but has not been replicated in subsequent studies (Choeyprasert et al., 2013) .
The association between hearing impairment and GSTT1 and GSTP1 loci, members of the glutathione S-transferases (GSTs) superfamily, was first described in survivors of adult cancer (Oldenburg et al., 2007) . GSTs are known to play an important role in cell protection by scavenging free radicals caused by cisplatin by conjugating it with glutathione (Peters et al., 2000; McIlwain et al., 2006) . In CCS, the association between cisplatin-induced hearing impairment and polymorphisms in the GST gene family (GSTP1, GSTT1, GSTM1, GSTM3, GSTZ1) was investigated in four studies (Choeyprasert et al., 2013; Ross et al., 2009; Peters et al., 2000; Rednam et al., 2013) . One study of 39 survivors identified the GSTM*B allele to be associated with a lower risk of hearing impairment (OR: 0.11, 95% CI not given, p-value: 0.02) (Peters et al., 2000) and a larger study of 86 medulloblastoma survivors found that survivors with the GSTP1 AG or the GG genotype had a greater risk of hearing impairment (OR 4.0, 95% CI: 1.2-13.6, p = 0.03) than survivors with the AA genotype (Rednam et al., 2013) . However, the latter finding may be false positive since the study by Ross et al (Ross et al., 2009) , in 162 subjects had 99.9% power to detect a similar effect at p ≤ 0.05, but did not find a significant association between the GSTP1 genotype and hearing impairment.
While no GWAS examining hearing impairment has been performed in CCS after completion of therapy, one GWAS in 238 subjects reported on susceptibility to cisplatin-induced hearing impairment measured during childhood cancer treatment (Xu et al., 2015) . Although this study did not meet the inclusion criterion of evaluation of the late effect after end treatment -the cisplatin-related hearing loss assessment was based on audiology data obtained between 9 and 24 months after the initiation of therapy-it yielded valuable results for this study field. This study identified one significant SNP in the ACYP2 gene (Xu et al., 2015) , which codes for an acylphosphatase that can influence Ca 2+ homeostasis in the cochlea and is involved in hair cell development (Fuchs, 2014) . This finding was replicated in an independent cohort of 156 CCS after treatment, although pooling of the results from both studies was needed to reach statistical significance (Vos et al., 2016) . This stresses the need not only for replication in independent studies, but also for adequately sized studies. The replication indicates there is no difference in genetic susceptibility in the cohorts with hearing impairment measured during or after treatment, which is in line with current knowledge concerning the irreversibility of hearing impairment. However, recent data suggests that in some survivors, cisplatininduced hearing impairment manifests later in life, suggesting that some cases of cisplatin-induced hearing impairment might be missed if hearing function is only measured during treatment (Clemens et al., 2017) . Up until now, no GWAS has been published to study the effect of genetic variation on hearing impairment in long-term CCS. In summary, the following genes were associated with hearing impairment in at least two independent sets of CCS subjects: COMT (rs4646316 and rs9332377, five reports, two significant (Ross et al., 2009; Pussegoda et al., 2013) ), TPMT (rs12201199, rs1142345, rs1800460, five reports, two significant (Ross et al., 2009; Pussegoda et al., 2013) ) and ACYP2 (rs1872328, two reports, two significant (Thiesen et al., 2017; Vos et al., 2016) ). Although large cohorts and replication cohorts are requirements for solid genetic research, many studies on hearing impairment do not meet these criteria. The functional significance is not fully understood for all SNPs and the clinical implication of polymorphisms in TPMT in hearing impairment has only been recently demonstrated in murine inner ear cells (Bhavsar et al., 2017) . The functional significance of polymorphisms in COMT in hearing impairment is still unclear.
Future directions
Among childhood cancer survivors the heterogeneity of late toxicities is broad, even in survivors who have been treated with the same protocols. This suggests a role for genetic variation. However, the evidence for an association between genetic variation and late toxicities after childhood cancer is largely insufficient or inconclusive to date, with few exceptions such as the reported associations between ACYP2 and hearing impairment. The inconclusive evidence is mainly due to a lack of well-designed, adequately powered studies. To date, in the reported late effects, only one GWAS has been performed. Especially in candidate gene studies, a) cohorts are small, b) replication cohorts are often lacking, c) the definitions used for biological endpoints are inconsistent across studies, and d) there are differences in study design across studies which hinders comparability. The lack of consistent associations across studies can be largely explained by methodological factors. In addition, variations in biological factors play an important role, since most of the outcomes studied are known to have multi-factorial etiologies, which include differences in genetic background, environment, behavioral factor, as well as co-morbidity. Moreover, clinical feasibility to collect data in a sufficiently powered and homogeneous cohort may play a role. Future research studies in this field could therefore benefit from considering the following principles.
Firstly, future studies need to include adequately sized cohorts in order to have sufficient power to identify low risk variants, which are the expected risk variants in common traits such as the evaluated late toxicities (i.e., common disease, common variant hypothesis). Several studies highlight the need for stratification or sub-analyses (Ross et al., 2004; Jones et al., 2008) , which again require larger study populations. Power calculations and adjustment for multiple testing are essential tools to minimize type 1 and 2 errors. GWASs are becoming more popular and are evaluating hundreds of thousands to millions of SNP markers at the same time and require a multiple testing adjustment to p < 5*10 −8 . Therefore large sample sizes are required to achieve sufficient statistical power (Hong and Park, 2012) . The number of SNPs to be included can increase exponentially when the sample size increases and studies with larger sample sizes are able to detect smaller associations as a result of higher power (Liu and Fu, 2015) . This highlights the need for international collaboration to assure sufficient sample sizes to identify genetic associations. Moreover, a large sample size is important as the focus of genetic studies in late toxicities after cancer often is on an interaction between treatment and a polymorphism, and interaction studies require even larger power than regular association studies.
Secondly, future genetic studies will benefit from inclusion of independent replication cohorts, as is common practice in the GWAS field, to strengthen the study design and avoid type I errors. Yet again this needs international collaboration to replicate findings in independent studies.
Thirdly, to ensure that the genetic difference observed between cohorts is related to the disease or condition under study and to rule-out spurious associations, inclusion of cohorts with similar genetic backgrounds (similar ethnicity) is preferred. For study situations, where this is not feasible by design, several methods have been developed to correct for ancestrally distinct populations, such as principal components analysis, based on the variance of the studied genotypes (Price et al., 2010) . To date, most genetic studies have been performed in Caucasians. Genetic analyses in all ethnicities are required to avoid disparities in addressing knowledge gaps related to genetic susceptibility to late treatment effects.
In addition, to increase the chance of replication of results, harmonization by consistent definitions of outcomes and evaluation of possible confounders are necessary. Also, sufficient understanding of the molecular mechanisms underlying the disease or condition is important to adequately define cases and controls. In this regard, the proper selection of cases and controls has been extensively discussed within genetic epidemiology (Hattersley and McCarthy, 2005) .
Next, it is essential that collection, processing, storage and retrieval of bio-specimens is conducted under quality control programs using standard operating procedures to guarantee low inter-sample variance and high quality of the samples. Within international collaborations, the establishment of an international biobank could be of value. Biobanks require high ethical practice standards, but offer research and researchers the possibility of cross-collaboration and synergy between different fields which is needed to further advance genetic research.
Finally, genetic technology is continuously improving, resulting in even bigger datasets with higher genetic resolution (MacArthur et al., 2017) . Yet, the same principles as described above apply and with even more necessity given the even larger number of genetic variants tested. With the increasing availability of commercially available arrays and increasing affordability of large-scale GWAS, performance, coverage and imputation quality should be considered when choosing an array. While whole genome sequencing and whole exome sequencing have gained considerable attention in genetic epidemiology, and are gaining ground in the diagnostic phase of childhood cancer, none of these approaches have yet been taken in the evaluation of genetic susceptibility to late effects in CCS.
Up until now, evidence-based guidelines for CCS concerning genetic susceptibility testing have only been developed for cardiotoxicity (Aminkeng et al., 2016b) . However, these guidelines are not implemented in clinical practice yet. For other late toxicities after childhood cancer the currently available literature is not robust enough, as yet, to inform reliable prediction models. However, genotyping childhood cancer patients in order to risk-adapt treatment based on risk models predicting susceptibility to specific late toxicities is likely to become standard of care. International collaboration is critical to advance knowledge of specific genetic risk factors in order to guide the development of scientifically rigorous prediction models. Currently, we are investigating the genetic susceptibility of hearing impairment and female gonadal impairment in an international consortium (European Union's Seventh Framework programme project PanCareLIFE) with replication planned in independent cohorts from North America (PanCareLIFE, 2017).
Conclusions
With growing knowledge of genetic determinants of late-effects and the continuation in decreasing genotyping costs, more personalized treatment protocols may become possible in the future. The criteria of 1) adequately sized cohorts and 2) the inclusion of independent replication cohorts are mandatory for well-founded research in genetic variability. International collaboration can ensure adherence to these criteria and thus be beneficial for the quality of research.
